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A 64 kilodalton (kDa) surface protein was isolated from the water-extracted materials from Mycohcterium bovb strain BCG, the determinants 
of which are antigenically shared by a 64 kDa major surface antigenic component of line IO hepatoma cells. The 64 kDa protein showed anti-lint 
10 tumor activity in pre-immunized guinea pigs, and this suggests that the BCG 64 kDa protein is probably identical with the tumor specific antigen. 
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1, INTRODUCTION 2. MATERIALS AND METHODS 
A number of studies have attempted to purify and 
characterize species-specific immunologically active 
mycobacterial ntigens associated with the host cellular 
immune responses [l-4]. However, one particular an- 
tigen from Mycobacterium bovis BCG, designated the 
64 kilodalton (kDa) antigen, has received much atten- 
tion because it appears to be one of the major soluble, 
immunologically active protein antigens [5-S]. Purified 
64 kDa antigen also elicited a strong delayed type 
hypersensitivity reaction in experimental animals and 
promoted a significant level of IgG antibody in sensitiz- 
ed guinea pigs [7]. 
Recently we described the presence of common an- 
M. bovis BCG has also been investigated widely 
within the scope of cancer immunotherapy of ex- 
perimental animals and humans [g-12]. Much effort 
has also been made to isolate the specific components 
possessing antitumor activity from BCG [ 13- 151, and 
there arc reports on the antigenic relationships between 
BCG and different animal tumor and human cancer 
cells [16-181. 
2.1. BCG and tumor cells 
Mycobacterium bows BCG (Tokyo strain 172) was cultured on 
Ogawa’s egg slants (Eiken Chemical Co., Tokyo) and inoculated into 
one liter of Dubos medium (Eiken Chemical Co., Tokyo) in five 
Erlenmeyer flasks and incubated at 37°C. After 2-3 weeks, the cells 
were separated by centrifugation at I6 000 x g for 25 min and washed 
in saline. 
Diethylnitrosamine induced line 10 hepatocarcinoma cells [to] in 
strain 2 guinea pigs, were maintained in ascitic form by serial passages 
(6-10 passages) and the ascitic fluid was collected between 12-16 days 
after the intrapcritoneal inoculation of the tumor cells. Viability of 
the tumor cells was checked by the Trypan blue dye exclusion method 
and the cells were washed in saline. 
The saline-washed BCG sells were suspended in 50 vols of distilled 
water. The suspension was mildly shaken (GO oscillations per min) for 
8 h at 37’C and centrifuged at I6 OCU x g for 30 min and the superna- 
tam was rc.ccntrifugcd at 105 Ooo x g for 2 h. The supernatant after 
ultracentrifugarion containing soluble waler extracted materials was 
lyophilizcd, 
The water extraction method for the lint 10 tumor cells differed a 
little where Ihc tumor ccl1 suspension in distilled water (25 vols) was 
shaken for I h at 37OC (211. 
tigenic determinants between surface extracts of line 10 
tumor cells (and others) and BCG, using BCG 
monoclonal antibodies [19], In this paper, we 
demonstrate a 64 kDa protein from BCG, which shares 
common antigenic determinants with lint 10 tumor cells 
and has anti-line 10 tumor activity in pre-immunized 
guirlca pigs. 
2.3, Tru~rsrrrissiori elcclrorr rrticroscony (TEMJ 
This wns performed to check the ;;rface al$earanccs of the BCG 
cells oftcr wiltcr extraction, whcrc satnplcs on copper grids supported 
by collodioli wcrc ncgotivcly stained by 1% uranyl mztatc and viewed 
under clcctron microscope at an nccclcrating voltage of 75 kV. 
2.4. Prnrchr e.whrario~r 
Protein content of all sanlplcs was estimated by using the Sigma 
Micro Protcln Dctc~tnlnatiotl Kit, 
2.5. fwlollm~ o./ rlrc /KG 6J kL)u imrcitr 
A 120.‘0 scpwetlnu pcl was mdc in rotnbination with a 5% stnckine 
~CI 122~ WJ approxinlatcly 300 pu of proccin of the water cxtraetcd 
materiulr from fHXi wti.1 applied to the pcl. The rcpnr;rlcd prolciiis ll
Volume 288, number I,2 FEES LETTERS 
gels were then either stained with Coomassie brilliant blue R250 (Bio- 
Rad) or periodic acid Schiff’s reagent, or transferred to nitrocellulose 
membranes [23]. The membrane was stained in 0.1% Ponceau red 
solution to visualize the proteins and the center of a 64 kDa band 
(BCG 64 kDa), as determined by the molecular weight standards, was 
cut out carefully, destained in phosphate buffered saline (PBS) and 
sonicatcd in 5 ml of PBS until the membrane reduced to a powder fine 
enough to pass through a 25-gauge hypodermic needle and was 
lyophilized [24]. The apparent molecular weight was estimated using 
the following proteins as standards: bovine albumin 66 kDa, egg 
albumin 45 kDa. glyceraldehyde-3-phosphate debydrogenase 36 kDa, 
carbonic anhydrase 29 kDa, trypsinogen 24 kDa and trypsin inhibitor 
20 kDa. 
3 
2.6. Immunization 
Adult rabbits were immunized at one week intervals with three in- 
tramuscular injections of the sonicated membrane containing the 
BCG 64 kDa (approximately 50 pg of protein/kg body weight), 
suspended in saline. Titers of antibodies in serum were checked by the 
gel diffusion test and sera (Rabbit anti BCG kDa) were collected 6 
days after the last injection and stored at -8O’C. 
2.7. Jmtttunoltlotting 
Contamination of other proteins with the BCG 64 kDa was studied 
by immunoblotting[23]. Approximately 30 pg of protein of the water 
extracted materials from BCG was applied to a lane of SDS-PAGE 
and the separated proteins in the gel were transferred to a 
nitrocellulose membrane for immunoblotting analysis, where rabbit 
anti-BCG 64 kDa served as the 1st antibody and alkaline phosphatase 
conjugated swine anti-rabbit immunoglobulins (DAKOPATTS) as 
the 2nd antibody. 
2.8. Anligenic cross-reacfivity 
Distribution of common antigenic determinant(s) between the BCG 
64 kDa and line 10 tumor cells were studied by the indirect im- 
munofluorescence techniques [19] and immunoblotting [23]. 
Tumor cells were fixed in absolute ethanol, washed with PBS and 
incubated with rabbit anti-BCG 64 kDa and fluorescein isothio- 
cyanate (FITC) conjugated anti-rahhit IgG (Cappel Lab. Inc. USA) 
as 1st and 2nd antibodies, respectively. Tumor cells treated with non- 
immunized rabbit serum RS 1st antibody served as control. 
Approximately 30 pg of protein of the water extracted materials 
from BCG and line IO tumor cells were applied to the SDS-PAGE and 
proceeded as described earlier (Immunoblotting). 
Fig. 1. Wafer-extracted materials from BCG showed one major pro- 
tein band of 64 kDa in SDS-PAGE after Coomassie brilliant blue 
R250 Staining (lane 2). No contamination of other proteins with BCG 
64 kDa was demonstrated by immunoblot analysis (lane 3), where 
rabbit anti-BCG 64 kDa served as the 1st antibody. Lane I ~110~s the 
mOkCUlar weight standards in kDa: bovine albumin 66, egg albumin 
45, glyceraldehyde-3-phosphate dehydrogenase 36, carbonic 
anhydrase 29, trypsinogen 24, and trypsin inhibitor 20. 
2.9. Anri-line IO lutnor oclivily 
Anti-line IO tumor activity of the BCG 64 kDa was demonstrated 
in strain 2 guinea pigs, which were immunized three times with one- 
week intervals with the sonicatcd membrane containing BCG 64 kDa 
(approximately 50 fig of protein/kg body weight). The titer of an- 
tibodies in sera was checked by the gel diffusion test and all animals 
were challenged with approximately I x IO6 live line IO tumor cells 
suspended in RPM1 1640 medium, intradermally, 6 days after the last 
immunization. All animals were observed for 40 days for the growth 
of tumors and the association of BCG 64 kDa in the in vivo rejection 
or inhibition of live tumor ccl1 challcngc in the animals were 
statistically analyzed by the Student’s f-test. Thirteen guinea pigs wcrc 
included in ~hc test group and 1Oguinca pigs served OS control, which 
were injected three times with one week intervals with fresh sonicatcd 
nitroccllulosc membrane (same turbidity as fw group). 
gesting the nature of the 64 kDa band to be a protein 
with carbohydrate moieties. Isolation of BCG 64 kDa 
with less or no contamination of other proteins was 
demonstrated by immunoblot analysis, where only a 
single band was developed on the nitrocellulose mem- 
brane (Fig. 1). 
3, RESULTS AND DISCUSSION 
The simple low ionic strength extraction by the use of 
distilled water has been used previously to release 
several protein components from bacteria and other 
sources [21,25,26]. One main advantage of the water 
extraction, as has been revealed by electron 
microscopy, is that it only removed the surface com- 
ponents of the cells without significantly affecting the 
morphological structures of the cells (data not shown), 
thus making subscqucnt purification of the surface pro- 
teins easier. Isolation of the soluble 64 kDa protein 
from the water extracted matcrinls also suggested that 
the BCG 64 kDa is a surface protein. 
The water-extracted materials howed one major pro- In recent studies, we described the major surface 
tein band of 64 kDa and some other low nlolccular components of line 10 hepatoma cells and their an- 
weight proteins in SDS-PAGE after Coomassic brilliant tigenicitics, whcrc 5 proteins with carbohydrate 
blue R250 staining (Fig. 1). The major band was also moieties of apparent molecular weights of 44,46,62,64 
faintly stainable in periodic acid Schiff’s reagent, sug- and 68 kDn were prominent [21], and sup$estcd COIW 
78 
August 1991 
Volume 288, number 1,2 FEBS LETTERS August 1991 
Fig. 2. Indirect immunofluorescence analysis showing sharp fluorescences from line 10 tumor cells treated with rabbit anti-BCG 64 kDa as the 1st 
antibody, suggesting that EKG 64 kDa and line 10 tumor cells have common antigenic determinant(s) (A, 800x). However, the tumor cells treated 
with non-immunized rabbit serum as 1st antibody did not show any fluorescence (B. 800x). 
mon antigenic determinants between the surface ex- 
tracts of line 10 tumor ceIIs (and others) and BCG using 
BCG-monoclonal antibodies [19]. In this study, the in- 
direct imrnunof’luorescence analysis showed sharp 
fluorescences from line 10 tumor cells treated with rab- 
bit anti-EKG 64 kDa (Fig. 2), indicating that the BCG 
64 kDa protein and line 10 tumor cells have antigenic 
determinant(s) incommon, which are probably present 
on the surfaces of the tumor cells. This is again sup- 
ported by the immunoblot analysis where a faint but 
clear band from line 10 tumor water-extracted 
materials, corresponding to the BCG 64 kDa band, was 
obtained on nitrocellulose membranes (data not 
shown). All these data combined, confirm each other 
and clearly indicate that the antigenic determinants be- 
tween the BCG 64 kDa and the 64 kDa major surface 
antigenic omponent of line 10 tumor cells are identical. 
Strong antitumor activity of BCG 64 kDa was clearly 
demonstrated in the test animals when compared with 
the control group, The experiment was repeated to 
check the reproducibility of the results, and the test 
animals which received BCG ti4 kDa showed cithcr 
complete rcjcction or partial inhibition of the tumor 
growth when observed for 40 days after tumor 
transplantation (Fig. 3). Howcvcr, the control animals 
which were injected with fresh sonictltcd mcmbranc on- 
ly, developed big tumors without much diffcrcncc in 
size, suggesting tllat the nitroccllutosc tnernbranc only 
acted as an adjuvant [24] md did not offcct the results 
of our cxperimcnts. Evidence thtlt the isolated BCG 64 
kDa can induce an immune response in normal guinea 
pigs is suggested by the fact that all immunized animals 
demonstrated significantly increased titers of anti-BCG 
64 kDa antibody. However, the most relevant and 
simultaneously the most stringent criterion for the func- 
tional integrity of the isolated BCG 64 kDa antigen, is 
the ability to induce protective tumor immunity in nor- 
BCG 64KD CONTROL 
Fig. 3. The tcs~ guinea pigs which wcrc immunized with the KG 64 
kDa, showed cithcr complete rejection or partial lnhibitlon of lint IO 
tumor growth when observed for 40 days after lunlor cell clrallst~gc. 
I-towvcr, all canlrol mitwhdcvclopcd big tumrs without much dlf- 
rcrcncc in skc arrcr tumor cell challcngc. 
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ma1 animals either by activating lymphocytes or by in- 
ducing Natural Killer (NK) cells by acting as an adju- 
vant, which eventually may inhibit the tumor cells. This 
criterion demands not only that BCG 64 kDa be im- 
munogenic but also that the level and type of immunity 
that is developed provide the immunized animals with 
the ability to reject or inhibit a viable tumor cell 
challenge. The anti-line 10 tumor activity of BCG 64 
kDa in the pre-immunized animals also suggests that 
BCG 64 kDa is probably identical with the tumor 
specific antigen. 
Sharing of antigenic determinants between BCG and 
line 10 tumor cells has also been suggested by others. 
Boros and Rapp found that sera from guinea pigs im- 
munized with BCG reacted with line 10 cells [16]. 
Minden and co-workers showed that the line 10 cells 
shared some determinants with BCG [17], and Bucana 
and Hanna used immunoelectronmicroscopy to 
demonstrate binding of anti-BCG to the surface of line 
10 and human melanoma cells 1271. Our study confirms 
these earlier firidings and additionally suggests that (i) 
antigenic determinants between the two 64 kDa surface 
proteins of BCG and line 10 hepatoma cells are com- 
mon and (ii) that the 64 kDa protein from BCG is pro- 
bably identical with the tumor specific antigen. 
Although we are not sure, at this stage of the work, 
about the identity or similarity of our BCG 64 kDa pro- 
tein and the BCG 64 kDa protein described by others 
[4-81, these data definitely provide us with a basis for 
the further characterization of the BCG 64 kDa protein 
as an agent for tumor diagnosis and therapy. 
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